Melanoma accounts for less than one percent of skin cancer cases, but the vast majority of skin cancer deaths.2 Although recreational exposure to the sun and a history of sunburn are major predisposing factors, detecting mutations in the BRAF gene can play an important role in guiding treatment options.
In 2011, Roche became the first company to receive simultaneous approval for a companion diagnostic and a therapy for BRAF - mutation positive advanced melanoma.
References